Ligand Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2017 - 2021
Period Ending	Jun '25 Jun 30, 2025	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	2017 - 2021
Cash & Equivalents	-	199.88	127.75	120.35	88.54	144.68	Upgrade
Cash & Short-Term Investments	199.88	199.88	127.75	120.35	88.54	144.68	Upgrade
Cash Growth	49.98%	56.46%	6.15%	35.93%	-38.80%	-34.06%	Upgrade
Accounts Receivable	-	2,539	2,378	1,421	1,158	1,315	Upgrade
Receivables	-	3,011	2,378	1,421	1,172	1,330	Upgrade
Inventory	-	1,893	1,823	1,353	845.18	684.42	Upgrade
Prepaid Expenses	-	-	224.05	260.1	159.61	126.6	Upgrade
Other Current Assets	-	1,460	1,003	739.97	418.73	407.54	Upgrade
Total Current Assets	-	6,564	5,556	3,895	2,684	2,693	Upgrade
Property, Plant & Equipment	-	6,453	5,728	4,879	4,052	4,156	Upgrade
Long-Term Investments	-	0.03	0	0	-	-	Upgrade
Other Intangible Assets	-	1.23	1.55	3.85	6.19	8.23	Upgrade
Other Long-Term Assets	-	415.44	409.37	341.29	251.07	257.43	Upgrade
Total Assets	-	13,434	11,695	9,118	6,994	7,115	Upgrade
Accounts Payable	-	1,548	1,190	1,102	693.31	893.05	Upgrade
Accrued Expenses	-	1,196	2,109	1,091	1,255	1,158	Upgrade
Short-Term Debt	-	-	741.61	666.06	706.19	562.65	Upgrade
Current Portion of Long-Term Debt	-	1,358	238.59	223.67	193.68	303.1	Upgrade
Other Current Liabilities	-	407.33	5.52	91.67	77.79	46.16	Upgrade
Total Current Liabilities	-	4,509	4,284	3,175	2,926	2,963	Upgrade
Long-Term Debt	-	351.34	992.38	1,597	1,112	1,231	Upgrade
Long-Term Deferred Tax Liabilities	-	427.28	279.79	112.54	10.69	68.11	Upgrade
Other Long-Term Liabilities	-	266.25	202.74	477.83	47.39	34.62	Upgrade
Total Liabilities	-	5,561	5,764	5,365	4,098	4,297	Upgrade
Common Stock	-	411.8	389.98	368.82	349.93	324.94	Upgrade
Additional Paid-In Capital	-	-	2,496	1,825	1,572	1,422	Upgrade
Retained Earnings	-	-	2,406	1,553	967.96	1,067	Upgrade
Comprehensive Income & Other	-	7,063	327.59	6.53	5.47	3.93	Upgrade
Total Common Equity	7,475	7,475	5,620	3,754	2,896	2,818	Upgrade
Minority Interest	-	397.21	311.72	-	-	-	Upgrade
Shareholders' Equity	7,872	7,872	5,931	3,754	2,896	2,818	Upgrade
Total Liabilities & Equity	-	13,434	11,695	9,118	6,994	7,115	Upgrade
Total Debt	1,709	1,709	1,973	2,486	2,012	2,097	Upgrade
Net Cash (Debt)	-1,509	-1,509	-1,845	-2,366	-1,923	-1,952	Upgrade
Net Cash Per Share	-7.41	-7.63	-9.56	-13.16	-11.50	-12.02	Upgrade
Filing Date Shares Outstanding	203.98	206.39	194.99	184.41	174.97	162.47	Upgrade
Total Common Shares Outstanding	203.98	206.39	194.99	184.41	174.97	162.47	Upgrade
Working Capital	-	2,055	1,271	720.1	-241.37	-270.18	Upgrade
Book Value Per Share	36.22	36.22	28.82	20.35	16.55	17.35	Upgrade
Tangible Book Value	7,474	7,474	5,618	3,750	2,890	2,810	Upgrade
Tangible Book Value Per Share	36.21	36.21	28.81	20.33	16.51	17.29	Upgrade
Land	-	-	235.8	227.16	214.67	201.31	Upgrade
Buildings	-	-	1,283	1,036	1,035	1,016	Upgrade
Machinery	-	-	4,868	3,776	3,767	3,725	Upgrade
Construction In Progress	-	-	683.62	971.65	-	21.77	Upgrade

Updated Jan 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.